The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHDNEW YORK, July 07, 2026 (GLOBE NEWSWIRE) ...
FOCUS-3 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of ...
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharm ...
By registering the LongCat-2.0 repository under the open-source MIT License, Meituan positions the architecture with maximum ...
Silevertinib, Black Diamond Therapeutics' lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR. Read why ...
Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...
Productivity happens on the road as well as in your home office. To make sure you can get things done, consider cashing in on ...
Full terms and rules for the Mashable at VidCon 2026 sweepstakes.
OFFICIAL SWEEPSTAKES RULES. NO PURCHASE NECESSARY TO ENTER OR WIN. A PURCHASE WILL NOT INCREASE YOUR CHANCES OF WINNING. VOID ...
Shares of uniQure QURE soared 78.4% on June 17, after the company announced a major regulatory milestone for AMT-130, its investigational gene therapy for Huntington's disease. The stock, however, ...
Background Improvement science has supported the methodological foundations for the application of quality improvement (QI) ...
We want to hear your thoughts on the PC brands you use (or manage) in a professional capacity. Take the survey for a chance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results